Xlife Sciences AG (SWX: XLS)
Switzerland
· Delayed Price · Currency is CHF 25.00
-0.40 (-1.57%)
Jan 3, 2025, 9:00 AM CET
Xlife Sciences AG Revenue
Xlife Sciences AG had revenue of 349.82K CHF in the half year ending June 30, 2024, a decrease of -6.08%. This brings the company's revenue in the last twelve months to 990.27K, down -1.32% year-over-year. In the year 2023, Xlife Sciences AG had annual revenue of 988.44K, down -3.85%.
Revenue (ttm)
990.27K
Revenue Growth
-1.32%
P/S Ratio
142.51
Revenue / Employee
58.25K
Employees
17
Market Cap
143.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 988.44K | -39.54K | -3.85% |
| Dec 31, 2022 | 1.03M | 221.91K | 27.53% |
| Dec 31, 2021 | 806.07K | 409.26K | 103.14% |
| Dec 31, 2020 | 396.81K | -118.02K | -22.92% |
| Dec 31, 2019 | 514.83K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 60.58B |
| Novartis AG | 42.18B |
| Lonza Group AG | 6.70B |
| Alcon | 8.25B |
| Galderma Group AG | 3.88B |
| Straumann Holding AG | 2.54B |
| Sonova Holding AG | 3.71B |
| Sandoz Group AG | 9.09B |